Why the study?
Does ticagrelor reduce the rate of stroke, myocardial infarction, or death at 90 days compared to aspirin in patients with acute ischemic stroke or transient ischemic attack?
Does ticagrelor reduce the rate of stroke, myocardial infarction, or death at 90 days compared to aspirin in patients with acute ischemic stroke or transient ischemic attack?
In patients with acute ischemic stroke or transient ischemic attack, ticagrelor is not superior to aspirin for preventing the composite of stroke, myocardial infarction, or death at 90 days.
Answers are grounded in this paper and cite their sources.
Supports aspirin monotherapy after acute ischemic stroke or TIA; confirms prior evidence against ticagrelor superiority.
In our trial involving patients with acute ischemic stroke or transient ischemic attack, ticagrelor was not found to be superior to aspirin in reducing the rate of stroke, myocardial infarction, or death at 90 days. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01994720.).
No takes yet. Share an insight, caveat, or question.
Johnston et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: